Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.
LifeNet Health has announced the acquisition of Tissue Testing Technologies LLC (T3), a South Carolina–based biotechnology company specializing in advanced biopreservation. The deal expands LifeNet Health’s capabilities in organ and tissue preservation by integrating proprietary vitrification and warming technologies developed by Tissue Testing Technologies. The transaction is positioned to enhance clinical transplantation success rates, support